1.
Bioorg Med Chem Lett
; 23(16): 4591-6, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23842474
RESUMO
The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compound and ion channel activity in particular. Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacology profiles. Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507.